BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
Opiant is a specialty pharmaceutical company developing medicines for addiction an...
Opiant is a specialty pharmaceutical company de...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...
Ultragenyx is a biopharmaceutical company commi...
We have used biochemical, molecular & cell biology and in vivo models to screen, i...
We have used biochemical, molecular & cell biol...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...
Osmotica Pharmaceuticals plc is a fully-integra...
Corcept is a pharmaceutical company engaged in the discovery, development and comm...
Corcept is a pharmaceutical company engaged in ...
Join the National Investor Network and get the latest information with your interests in mind.